Brief: ANI Pharmaceuticals Q1 Adjusted EPS USD 2.05 Vs. IBES Estimate USD 1.3
08/05/2026 11:50
May 08 (Reuters) - ANI Pharmaceuticals Q1 net income USD 29.5 million. Q1 adjusted EBITDA USD 63 million Q1 EPS USD 1.28 Q1 revenue USD 237.5 million vs. IBES estimate USD 207.6 million outlook FY adjusted EBITDA USD 285-300 million outlook FY revenue USD 1,080-1,140 million vs. IBES estimate USD 1,050 million outlook FY adjusted EPS USD 9.19-9.69 vs. IBES estimate USD 9.07
Recent news on ANI Pharmaceuticals
See all newsBrief: Ani Pharmaceuticals Announces The Launch Of Duloxetine Delayed-Release Capsules
Brief: Ani Pharmaceuticals Announces The FDA Approval Of Everolimus Tablets For Oral Suspension
Brief: Ani Pharmaceuticals Appoints Henry Gosebruch To Board Of Directors
U.S. RESEARCH ROUNDUP-Compass Minerals, Duke Energy, Tesla
ANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary